Formycon AG (FRA:FYB)

Market Cap	522.64M
Revenue (ttm)	69.67M
Net Income (ttm)	-125.67M
Shares Out	n/a
EPS (ttm)	-7.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,062
Average Volume	39,231
Open	30.05
Previous Close	29.60
Day's Range	28.95 - 30.20
52-Week Range	19.18 - 64.40
Beta	n/a
RSI	64.26
Earnings Date	Aug 13, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 250
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FYB